Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 135 entries
Sorted by: Best Match Show Resources per page
Effects of treadmill exercise on hippocampal neurogenesis in an MPTP /probenecid-induced Parkinson's disease mouse model.

Journal of physical therapy science

Sung YH.
PMID: 26644675
J Phys Ther Sci. 2015 Oct;27(10):3203-6. doi: 10.1589/jpts.27.3203. Epub 2015 Oct 30.

[Purpose] This study aimed to investigate the effect of treadmill exercise on non-motor function, specifically long-term memory, in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid-induced Parkinson's disease mouse model. [Methods] A mouse model of Parkinson's disease was developed by injecting 20 mg/kg of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine...

Cite
Sung YH. Effects of treadmill exercise on hippocampal neurogenesis in an MPTP /probenecid-induced Parkinson's disease mouse model. J Phys Ther Sci. 2015;27(10):3203-6doi: 10.1589/jpts.27.3203.
Sung, Y. H. (2015). Effects of treadmill exercise on hippocampal neurogenesis in an MPTP /probenecid-induced Parkinson's disease mouse model. Journal of physical therapy science, 27(10), 3203-6. https://doi.org/10.1589/jpts.27.3203
Sung, Yun-Hee. "Effects of treadmill exercise on hippocampal neurogenesis in an MPTP /probenecid-induced Parkinson's disease mouse model." Journal of physical therapy science vol. 27,10 (2015): 3203-6. doi: https://doi.org/10.1589/jpts.27.3203
Sung YH. Effects of treadmill exercise on hippocampal neurogenesis in an MPTP /probenecid-induced Parkinson's disease mouse model. J Phys Ther Sci. 2015 Oct;27(10):3203-6. doi: 10.1589/jpts.27.3203. Epub 2015 Oct 30. PMID: 26644675; PMCID: PMC4668166.
Copy Download .nbib Format: NLM
Drug resistance in cortical and hippocampal slices from resected tissue of epilepsy patients: no significant impact of p-glycoprotein and multidrug resistance-associated proteins.

Frontiers in neurology

Sandow N, Kim S, Raue C, Päsler D, Klaft ZJ, Antonio LL, Hollnagel JO, Kovacs R, Kann O, Horn P, Vajkoczy P, Holtkamp M, Meencke HJ, Cavalheiro EA, Pragst F, Gabriel S, Lehmann TN, Heinemann U.
PMID: 25741317
Front Neurol. 2015 Feb 18;6:30. doi: 10.3389/fneur.2015.00030. eCollection 2015.

Drug resistant patients undergoing epilepsy surgery have a good chance to become sensitive to anticonvulsant medication, suggesting that the resected brain tissue is responsible for drug resistance. Here, we address the question whether P-glycoprotein (Pgp) and multidrug resistance-associated proteins...

Cite
Sandow N, Kim S, Raue C, et al. Drug resistance in cortical and hippocampal slices from resected tissue of epilepsy patients: no significant impact of p-glycoprotein and multidrug resistance-associated proteins. Front Neurol. 2015;6:30doi: 10.3389/fneur.2015.00030.
Sandow, N., Kim, S., Raue, C., Päsler, D., Klaft, Z. J., Antonio, L. L., Hollnagel, J. O., Kovacs, R., Kann, O., Horn, P., Vajkoczy, P., Holtkamp, M., Meencke, H. J., Cavalheiro, E. A., Pragst, F., Gabriel, S., Lehmann, T. N., & Heinemann, U. (2015). Drug resistance in cortical and hippocampal slices from resected tissue of epilepsy patients: no significant impact of p-glycoprotein and multidrug resistance-associated proteins. Frontiers in neurology, 630. https://doi.org/10.3389/fneur.2015.00030
Sandow, Nora, et al. "Drug resistance in cortical and hippocampal slices from resected tissue of epilepsy patients: no significant impact of p-glycoprotein and multidrug resistance-associated proteins." Frontiers in neurology vol. 6 (2015): 30. doi: https://doi.org/10.3389/fneur.2015.00030
Sandow N, Kim S, Raue C, Päsler D, Klaft ZJ, Antonio LL, Hollnagel JO, Kovacs R, Kann O, Horn P, Vajkoczy P, Holtkamp M, Meencke HJ, Cavalheiro EA, Pragst F, Gabriel S, Lehmann TN, Heinemann U. Drug resistance in cortical and hippocampal slices from resected tissue of epilepsy patients: no significant impact of p-glycoprotein and multidrug resistance-associated proteins. Front Neurol. 2015 Feb 18;6:30. doi: 10.3389/fneur.2015.00030. eCollection 2015. PMID: 25741317; PMCID: PMC4332373.
Copy Download .nbib Format: NLM
Metformin Prevents Dopaminergic Neuron Death in MPTP/P-Induced Mouse Model of Parkinson's Disease via Autophagy and Mitochondrial ROS Clearance.

The international journal of neuropsychopharmacology

Lu M, Su C, Qiao C, Bian Y, Ding J, Hu G.
PMID: 27207919
Int J Neuropsychopharmacol. 2016 Sep 21;19(9). doi: 10.1093/ijnp/pyw047. Print 2016 Sep.

BACKGROUND: Our previous study demonstrated that metabolic inflammation exacerbates dopaminergic neuronal degeneration in type 2 diabetes mice. Metformin, a typical oral hypoglycemic agent for diabetes, has been regarded as an activator of AMP-activated protein kinase and a regulator of...

Cite
Lu M, Su C, Qiao C, et al. Metformin Prevents Dopaminergic Neuron Death in MPTP/P-Induced Mouse Model of Parkinson's Disease via Autophagy and Mitochondrial ROS Clearance. Int J Neuropsychopharmacol. 2016;19(9)doi: 10.1093/ijnp/pyw047.
Lu, M., Su, C., Qiao, C., Bian, Y., Ding, J., & Hu, G. (2016). Metformin Prevents Dopaminergic Neuron Death in MPTP/P-Induced Mouse Model of Parkinson's Disease via Autophagy and Mitochondrial ROS Clearance. The international journal of neuropsychopharmacology, 19(9), . https://doi.org/10.1093/ijnp/pyw047
Lu, Ming, et al. "Metformin Prevents Dopaminergic Neuron Death in MPTP/P-Induced Mouse Model of Parkinson's Disease via Autophagy and Mitochondrial ROS Clearance." The international journal of neuropsychopharmacology vol. 19,9 (2016). doi: https://doi.org/10.1093/ijnp/pyw047
Lu M, Su C, Qiao C, Bian Y, Ding J, Hu G. Metformin Prevents Dopaminergic Neuron Death in MPTP/P-Induced Mouse Model of Parkinson's Disease via Autophagy and Mitochondrial ROS Clearance. Int J Neuropsychopharmacol. 2016 Sep 21;19(9). doi: 10.1093/ijnp/pyw047. Print 2016 Sep. PMID: 27207919; PMCID: PMC5043649.
Copy Download .nbib Format: NLM
NTP Toxicology and Carcinogenesis Studies of Probenecid (CAS No. 57-66-9) in F344/N Rats and B6C3F1 (Gavage Studies).

National Toxicology Program technical report series

[No authors listed]
PMID: 12637964
Natl Toxicol Program Tech Rep Ser. 1991 Sep;395:1-215.

Probenecid is a white crystalline solid commonly used as a uricosuric agent in the treatment of gout. Because of its inhibitory effects on renal tubule transport processes, probenecid is also used as a therapeutic adjunct to enhance blood levels...

Cite
NTP Toxicology and Carcinogenesis Studies of Probenecid (CAS No. 57-66-9) in F344/N Rats and B6C3F1 (Gavage Studies). Natl Toxicol Program Tech Rep Ser. 1991;395:1-215
(1991). NTP Toxicology and Carcinogenesis Studies of Probenecid (CAS No. 57-66-9) in F344/N Rats and B6C3F1 (Gavage Studies). National Toxicology Program technical report series, 3951-215.
"NTP Toxicology and Carcinogenesis Studies of Probenecid (CAS No. 57-66-9) in F344/N Rats and B6C3F1 (Gavage Studies)." National Toxicology Program technical report series vol. 395 (1991): 1-215.
NTP Toxicology and Carcinogenesis Studies of Probenecid (CAS No. 57-66-9) in F344/N Rats and B6C3F1 (Gavage Studies). Natl Toxicol Program Tech Rep Ser. 1991 Sep;395:1-215. PMID: 12637964.
Copy Download .nbib Format: NLM
Modulation of sinusoidal and canalicular elimination of bilirubin-glucuronides by rifampicin and other cholestatic drugs in a sandwich culture of rat hepatocytes.

Hepatology research : the official journal of the Japan Society of Hepatology

Lengyel G, Veres Z, Tugyi R, Vereczkey L, Molnár T, Glavinas H, Krajcsi P, Jemnitz K.
PMID: 17760873
Hepatol Res. 2008 Mar;38(3):300-9. doi: 10.1111/j.1872-034X.2007.00255.x. Epub 2007 Aug 29.

AIM: Drug-induced hyperbilirubinemia has been shown to often be derived from modulation of the expression and activity of hepatobiliary transporters. In this study we examined the interactions of some therapeutic agents, which have been shown to cause cholestasis, with...

Cite
Lengyel G, Veres Z, Tugyi R, et al. Modulation of sinusoidal and canalicular elimination of bilirubin-glucuronides by rifampicin and other cholestatic drugs in a sandwich culture of rat hepatocytes. Hepatol Res. 2007;38(3):300-9doi: 10.1111/j.1872-034X.2007.00255.x.
Lengyel, G., Veres, Z., Tugyi, R., Vereczkey, L., Molnár, T., Glavinas, H., Krajcsi, P., & Jemnitz, K. (2008). Modulation of sinusoidal and canalicular elimination of bilirubin-glucuronides by rifampicin and other cholestatic drugs in a sandwich culture of rat hepatocytes. Hepatology research : the official journal of the Japan Society of Hepatology, 38(3), 300-9. https://doi.org/10.1111/j.1872-034X.2007.00255.x
Lengyel, György, et al. "Modulation of sinusoidal and canalicular elimination of bilirubin-glucuronides by rifampicin and other cholestatic drugs in a sandwich culture of rat hepatocytes." Hepatology research : the official journal of the Japan Society of Hepatology vol. 38,3 (2008): 300-9. doi: https://doi.org/10.1111/j.1872-034X.2007.00255.x
Lengyel G, Veres Z, Tugyi R, Vereczkey L, Molnár T, Glavinas H, Krajcsi P, Jemnitz K. Modulation of sinusoidal and canalicular elimination of bilirubin-glucuronides by rifampicin and other cholestatic drugs in a sandwich culture of rat hepatocytes. Hepatol Res. 2008 Mar;38(3):300-9. doi: 10.1111/j.1872-034X.2007.00255.x. Epub 2007 Aug 29. PMID: 17760873.
Copy Download .nbib Format: NLM
Advances in the management of gout: critical appraisal of febuxostat in the control of hyperuricemia.

International journal of nephrology and renovascular disease

Beara-Lasic L, Pillinger MH, Goldfarb DS.
PMID: 21694922
Int J Nephrol Renovasc Dis. 2010;3:1-10. doi: 10.2147/ijnrd.s5563. Epub 2010 Feb 09.

Gout recently passed rheumatoid arthritis to become the most common inflammatory arthritis in the United States (US). However, epidemiologic studies indicate that the quality of gout management is suboptimal owing to both patient and physician issues. Only three options...

Cite
Beara-Lasic L, Pillinger MH, Goldfarb DS. Advances in the management of gout: critical appraisal of febuxostat in the control of hyperuricemia. Int J Nephrol Renovasc Dis. 2010;3:1-10doi: 10.2147/ijnrd.s5563.
Beara-Lasic, L., Pillinger, M. H., & Goldfarb, D. S. (2010). Advances in the management of gout: critical appraisal of febuxostat in the control of hyperuricemia. International journal of nephrology and renovascular disease, 31-10. https://doi.org/10.2147/ijnrd.s5563
Beara-Lasic, Lada, et al. "Advances in the management of gout: critical appraisal of febuxostat in the control of hyperuricemia." International journal of nephrology and renovascular disease vol. 3 (2010): 1-10. doi: https://doi.org/10.2147/ijnrd.s5563
Beara-Lasic L, Pillinger MH, Goldfarb DS. Advances in the management of gout: critical appraisal of febuxostat in the control of hyperuricemia. Int J Nephrol Renovasc Dis. 2010;3:1-10. doi: 10.2147/ijnrd.s5563. Epub 2010 Feb 09. PMID: 21694922; PMCID: PMC3108781.
Copy Download .nbib Format: NLM
Cytotoxicity of 2-tert-butyl hydroquinone glutathione conjugates after apical and basolateral exposure of rat renal proximal tubular cell monolayers.

Toxicology in vitro : an international journal published in association with BIBRA

Haenen HE, Bleijlevens E, Elzerman H, Temmink JH, Koeman JH, Van Bladeren PJ.
PMID: 20650192
Toxicol In Vitro. 1996 Apr;10(2):141-8. doi: 10.1016/0887-2333(95)00116-6.

Confluent monolayers of renal proximal tubular (RPT) cells cultured on porous supports were used to investigate the cytotoxicity induced by glutathione conjugates of 2-tert-butyl-(1,4)-hydroquinone (SG-TBHQ) after apical and basolateral exposure. As judged from lactate dehydrogenase (LDH) leakage, cytotoxicity was...

Cite
Haenen HE, Bleijlevens E, Elzerman H, et al. Cytotoxicity of 2-tert-butyl hydroquinone glutathione conjugates after apical and basolateral exposure of rat renal proximal tubular cell monolayers. Toxicol In Vitro. 1996;10(2):141-8doi: 10.1016/0887-2333(95)00116-6.
Haenen, H. E., Bleijlevens, E., Elzerman, H., Temmink, J. H., Koeman, J. H., & Van Bladeren, P. J. (1996). Cytotoxicity of 2-tert-butyl hydroquinone glutathione conjugates after apical and basolateral exposure of rat renal proximal tubular cell monolayers. Toxicology in vitro : an international journal published in association with BIBRA, 10(2), 141-8. https://doi.org/10.1016/0887-2333(95)00116-6
Haenen, H E, et al. "Cytotoxicity of 2-tert-butyl hydroquinone glutathione conjugates after apical and basolateral exposure of rat renal proximal tubular cell monolayers." Toxicology in vitro : an international journal published in association with BIBRA vol. 10,2 (1996): 141-8. doi: https://doi.org/10.1016/0887-2333(95)00116-6
Haenen HE, Bleijlevens E, Elzerman H, Temmink JH, Koeman JH, Van Bladeren PJ. Cytotoxicity of 2-tert-butyl hydroquinone glutathione conjugates after apical and basolateral exposure of rat renal proximal tubular cell monolayers. Toxicol In Vitro. 1996 Apr;10(2):141-8. doi: 10.1016/0887-2333(95)00116-6. PMID: 20650192.
Copy Download .nbib Format: NLM
Variability of treatment for gouty arthritis between rheumatologists and primary care physicians.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases

Medellin MV, Erickson AR, Enzenauer RJ.
PMID: 19078113
J Clin Rheumatol. 1997 Feb;3(1):24-7. doi: 10.1097/00124743-199702000-00005.

Wide variability exists in the treatment of gout. We compared the treatment practices of rheumatologists with those of primary care physicians (PCPs) in the management of gout. Pharmacy records were reviewed to identify patients treated with colchicine, allopurinol, probenecid,...

Cite
Medellin MV, Erickson AR, Enzenauer RJ. Variability of treatment for gouty arthritis between rheumatologists and primary care physicians. J Clin Rheumatol. 1997;3(1):24-7doi: 10.1097/00124743-199702000-00005.
Medellin, M. V., Erickson, A. R., & Enzenauer, R. J. (1997). Variability of treatment for gouty arthritis between rheumatologists and primary care physicians. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 3(1), 24-7. https://doi.org/10.1097/00124743-199702000-00005
Medellin, M V, et al. "Variability of treatment for gouty arthritis between rheumatologists and primary care physicians." Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases vol. 3,1 (1997): 24-7. doi: https://doi.org/10.1097/00124743-199702000-00005
Medellin MV, Erickson AR, Enzenauer RJ. Variability of treatment for gouty arthritis between rheumatologists and primary care physicians. J Clin Rheumatol. 1997 Feb;3(1):24-7. doi: 10.1097/00124743-199702000-00005. PMID: 19078113.
Copy Download .nbib Format: NLM
Evidence of active transport involvement in morphine transport via MDCKII and MDCK-PGP cell lines.

Research in pharmaceutical sciences

Mashayekhi SO, Sattari MR, Routledge PA.
PMID: 21589798
Res Pharm Sci. 2010 Jul;5(2):99-106.

Several transporters appear to be important in transporting various drugs. Many patients, who receive morphine as analgesic medication, also receive other medications with potency of changing morphine transport by affecting P-glycoprotein (P-GP) and oatp2 transport system. This could influence...

Cite
Mashayekhi SO, Sattari MR, Routledge PA. Evidence of active transport involvement in morphine transport via MDCKII and MDCK-PGP cell lines. Res Pharm Sci. 2010;5(2):99-106
Mashayekhi, S. O., Sattari, M. R., & Routledge, P. A. (2010). Evidence of active transport involvement in morphine transport via MDCKII and MDCK-PGP cell lines. Research in pharmaceutical sciences, 5(2), 99-106.
Mashayekhi, S O, et al. "Evidence of active transport involvement in morphine transport via MDCKII and MDCK-PGP cell lines." Research in pharmaceutical sciences vol. 5,2 (2010): 99-106.
Mashayekhi SO, Sattari MR, Routledge PA. Evidence of active transport involvement in morphine transport via MDCKII and MDCK-PGP cell lines. Res Pharm Sci. 2010 Jul;5(2):99-106. PMID: 21589798; PMCID: PMC3093627.
Copy Download .nbib Format: NLM
Monolayers of IEC-18 cells as an in vitro model for screening the passive transcellular and paracellular transport across the intestinal barrier: comparison of active and passive transport with the human colon carcinoma Caco-2 cell line.

Environmental toxicology and pharmacology

Versantvoort CH, Ondrewater RC, Duizer E, Van de Sandt JJ, Gilde AJ, Groten JP.
PMID: 21782616
Environ Toxicol Pharmacol. 2002 Jul;11(3):335-44. doi: 10.1016/s1382-6689(01)00122-3.

PURPOSE: previous studies have shown that the rat small intestinal cell line IEC-18 provides a size-selective barrier for paracellularly transported hydrophilic macromolecules. In order to determine the utility of IEC-18 cells as an in vitro model to screen the...

Cite
Versantvoort CH, Ondrewater RC, Duizer E, et al. Monolayers of IEC-18 cells as an in vitro model for screening the passive transcellular and paracellular transport across the intestinal barrier: comparison of active and passive transport with the human colon carcinoma Caco-2 cell line. Environ Toxicol Pharmacol. 2002;11(3):335-44doi: 10.1016/s1382-6689(01)00122-3.
Versantvoort, C. H., Ondrewater, R. C., Duizer, E., Van de Sandt, J. J., Gilde, A. J., & Groten, J. P. (2002). Monolayers of IEC-18 cells as an in vitro model for screening the passive transcellular and paracellular transport across the intestinal barrier: comparison of active and passive transport with the human colon carcinoma Caco-2 cell line. Environmental toxicology and pharmacology, 11(3), 335-44. https://doi.org/10.1016/s1382-6689(01)00122-3
Versantvoort, Carolien H M, et al. "Monolayers of IEC-18 cells as an in vitro model for screening the passive transcellular and paracellular transport across the intestinal barrier: comparison of active and passive transport with the human colon carcinoma Caco-2 cell line." Environmental toxicology and pharmacology vol. 11,3 (2002): 335-44. doi: https://doi.org/10.1016/s1382-6689(01)00122-3
Versantvoort CH, Ondrewater RC, Duizer E, Van de Sandt JJ, Gilde AJ, Groten JP. Monolayers of IEC-18 cells as an in vitro model for screening the passive transcellular and paracellular transport across the intestinal barrier: comparison of active and passive transport with the human colon carcinoma Caco-2 cell line. Environ Toxicol Pharmacol. 2002 Jul;11(3):335-44. doi: 10.1016/s1382-6689(01)00122-3. PMID: 21782616.
Copy Download .nbib Format: NLM
Reduced febrile responses to peripheral and central administration of pyrogen in aged squirrel monkeys.

Neurobiology of aging

Clark SM, Gean JT, Lipton JM.
PMID: 24279943
Neurobiol Aging. 1980;1(2):175-80. doi: 10.1016/0197-4580(80)90013-5.

There is long-standing controversy as to whether fever capacity is reduced in aged man. Although loss of this cardinal sign of disease would be an impediment to diagnosis and treatment, there has been no previous research on altered febrile...

Cite
Clark SM, Gean JT, Lipton JM. Reduced febrile responses to peripheral and central administration of pyrogen in aged squirrel monkeys. Neurobiol Aging. 1980;1(2):175-80doi: 10.1016/0197-4580(80)90013-5.
Clark, S. M., Gean, J. T., & Lipton, J. M. (1980). Reduced febrile responses to peripheral and central administration of pyrogen in aged squirrel monkeys. Neurobiology of aging, 1(2), 175-80. https://doi.org/10.1016/0197-4580(80)90013-5
Clark, S M, et al. "Reduced febrile responses to peripheral and central administration of pyrogen in aged squirrel monkeys." Neurobiology of aging vol. 1,2 (1980): 175-80. doi: https://doi.org/10.1016/0197-4580(80)90013-5
Clark SM, Gean JT, Lipton JM. Reduced febrile responses to peripheral and central administration of pyrogen in aged squirrel monkeys. Neurobiol Aging. 1980;1(2):175-80. doi: 10.1016/0197-4580(80)90013-5. PMID: 24279943.
Copy Download .nbib Format: NLM
Lesinurad: A significant advancement or just another addition to existing therapies of gout?.

Journal of pharmacology & pharmacotherapeutics

Gupta A, Sharma PK, Misra AK, Singh S.
PMID: 28163535
J Pharmacol Pharmacother. 2016 Oct-Dec;7(4):155-158. doi: 10.4103/0976-500X.195897.

Gout is a metabolic disorder that usually presents as recurrent episodes of acute arthritis due to deposition of crystals in joints and cartilages. Despite the availability of several drugs for gout, its management is still less than adequate. There...

Cite
Gupta A, Sharma PK, Misra AK, et al. Lesinurad: A significant advancement or just another addition to existing therapies of gout?. J Pharmacol Pharmacother. 2016;7(4):155-158doi: 10.4103/0976-500X.195897.
Gupta, A., Sharma, P. K., Misra, A. K., & Singh, S. (2016). Lesinurad: A significant advancement or just another addition to existing therapies of gout?. Journal of pharmacology & pharmacotherapeutics, 7(4), 155-158. https://doi.org/10.4103/0976-500X.195897
Gupta, Ajay, et al. "Lesinurad: A significant advancement or just another addition to existing therapies of gout?." Journal of pharmacology & pharmacotherapeutics vol. 7,4 (2016): 155-158. doi: https://doi.org/10.4103/0976-500X.195897
Gupta A, Sharma PK, Misra AK, Singh S. Lesinurad: A significant advancement or just another addition to existing therapies of gout?. J Pharmacol Pharmacother. 2016 Oct-Dec;7(4):155-158. doi: 10.4103/0976-500X.195897. PMID: 28163535; PMCID: PMC5242027.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 135 entries